BPC-157 repair claims leave a lot unanswered.
“Repair” sounds reassuring when something hurts. With BPC-157, I want to know what was repaired and in whom. A rat tendon is a very different starting point from your sore shoulder.
The tendon result was in rats
To make BPC-157, a lab joins amino acids—the building blocks in proteins—into one small peptide chain. Its design follows part of a protein reported in stomach juice. That origin doesn't establish what it will do in a person.
In a study of cut rat Achilles tendons, BPC-157 improved strength and healing measures. That's a finding about injured rat tissue. It doesn't give us a recovery timetable for a human injury.
Most of the repair research is animal work. The review of muscle, bone and tendon healing describes a much thinner human record. An encouraging animal result can justify more research without settling whether a treatment helps people.
The human picture is much smaller.
Two people can't settle safety
A small intravenous safety study gave BPC-157 into a vein in two adults. It reported no observed side effects or meaningful changes in the safety tests it measured. It didn't test injury healing.
Two people is the number that matters here. A study that small has little chance of finding an uncommon problem. It also can't answer what happens over a long period.
The FDA's review of human studies found too little information to establish a safety profile. The studies were small and short, and safety monitoring was often unclear. That leaves the ordinary question open: do the possible benefits outweigh the risks for a particular injury?
No reported harm is reassuring, within the limits of a tiny study.
The unknowns include possible harm
BPC-157 isn't an FDA-approved medicine. FDA flags possible immune reactions and peptide impurities. An immune reaction means the body may treat the peptide as an invader; these studies don't tell us how often that might happen.
Research on new blood-vessel growth also raises a theoretical question about cancer, since tumours need a blood supply. That isn't evidence that BPC-157 causes cancer. Human research hasn't settled the question either way.
On the FDA page current as of April 22, 2026, BPC-157 is nominated but withdrawn. Withdrawal isn't clearance or approval for compounding. For an injury, a licensed U.S. clinician can assess the cause and discuss established care, including through telehealth where suitable. The comparison page helps untangle the research claims.